NAD+-Dependent Upregulation of MCT1 Expression to Restore Neuronal Ketone Metabolism

This hypothesis proposes that NAD+ precursor supplementation can restore neuronal ketone body utilization by activating SIRT1-mediated upregulation of MCT1 (monocarboxylate transporter 1). In neurodegenerative conditions, chronic PARP1 activation depletes cellular NAD+ pools, leading to reduced SIRT1 activity and subsequent downregulation of MCT1 expression. This creates a metabolic catastrophe where neurons lose their ability to efficiently transport and utilize ketone bodies as an alternative energy source when glucose metabolism is compromised. By supplementing with NAD+ precursors (such as nicotinamide riboside or NMN), cellular NAD+ levels are restored, reactivating SIRT1 deacetylase activity. SIRT1 then deacetylates key transcription factors and histone proteins at the SLC16A1 promoter region, enhancing MCT1 gene expression. The resulting increase in MCT1 protein levels on neuronal membranes restores efficient ketone body uptake, providing neurons with a critical alternative fuel source that can bypass defective glycolytic pathways. This mechanism is particularly relevant in conditions like Alzheimer’s disease, where both NAD+ depletion and impaired glucose metabolism converge to create energy deficits. The hypothesis predicts that NAD+ precursor treatment will show dose-dependent increases in both neuronal MCT1 expression and ketone body utilization rates, with corresponding improvements in neuronal bioenergetics and survival under metabolic stress conditions.